Company plans to triage a panel of antibodies towards first in human studies Cambridge, UK. December 16 2022 – Alchemab Therapeutics, a biotechnology company unlocking new therapies from within the immune system, today announced that it has been awarded a grant of £1.7 million (US$2 million) from Innovate UK’s Biomedical Catalyst (‘BMC’) 2022 funding competition, […]

Our Co-Founder and CSO Jane Osbourn was delighted to speak with her longtime friend Ahuva Nissim, antibody and therapeutic engineering professor at William Harvey Research Institute, Queen Mary University of London, about the career path that took her from studying molecular biology and building human phage libraries to developing therapeutics with convergent protective antibodies. She […]

Thank you to Nature Biotechnology for including Alchemab in NBT’s Class of 2021 biotechs! Their article features an interview with Jane Osbourn, Olivia Cavlan and Young Kwon alongside some very exciting startups. Read the whole story here.

Many thanks to Chloe Kent at In Vivo for her great interview with our CEO Young Kwon. In her story, titled Alchemab Is Bringing A New Meaning To Patient Centered Care, Chloe explores how the first step in our drug discovery journey starts with individual patients. As we target diseases across neurology and oncology through […]

Alchemab was delighted to be featured in Nature Biotechnology in a profile by Michael Eisenstein. In the article he speaks with Young Kwon, our CEO, and Jane Osbourn, our founder and CSO, about Alchemab’s revolutionary approach of looking for protective antibodies in ‘resilient’ people which may provide a new approach for discovering drug targets: “Our […]

Waltham, Massachusetts and Cambridge, UK May 26, 2022 – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, announced that Young T. Kwon, PhD, Alchemab’s Chief Financial and Operating Officer, has succeeded Douglas A. Treco, PhD as Chief Executive Officer and member of […]

Boston, Massachusetts and Cambridge, UK May 19, 2022 – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, today announced the publication of research demonstrating the potential of AntiBERTa (Antibody-specific Bi-directional Encoder Representation and Transformers), a transformer neural network that reads the components […]

Boston, Massachusetts and Cambridge, UK March 22, 2022 – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, has been selected by NVIDIA to harness the power of  the UK’s most powerful supercomputer, Cambridge-1. Alchemab will use the NVIDIA DGX SuperPOD supercomputing cluster, […]

Boston, Massachusetts and Cambridge, UK March 7, 2022 – Alchemab Therapeutics – a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology, has announced an extension of its collaboration with Medicines Discovery Catapult (MDC), a national facility enabling the UK’s community to accelerate innovative drug discovery. The collaboration […]

Boston, Massachusetts and Cambridge, UK November 15, 2021 – Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies in neurodegeneration and oncology, today announced the appointment of Young T. Kwon, PhD as Chief Financial and Operating Officer. “We are thrilled to welcome Young to the Alchemab management team and […]